<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Clinical and experimental studies suggest cross-talk between <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism and the renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) in atherogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to explore interactions between these two systems in mediating <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A prospective cohort of 4,160 Chinese patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, free of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> at enrollment, were analyzed using Cox models </plain></SENT>
<SENT sid="3" pm="."><plain>Interaction of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors (angiotensin I-converting <z:chebi fb="0" ids="23924">enzyme inhibitors</z:chebi> or <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blockers) and <z:chebi fb="0" ids="35664">statins</z:chebi> was estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S) </plain></SENT>
<SENT sid="4" pm="."><plain>RERI &gt; 0, AP &gt; 0, or S &gt; 1 indicates additive interaction between the two classes of drugs </plain></SENT>
<SENT sid="5" pm="."><plain>Molecular mechanisms underlying these interactions were explored using a uninephrectomy (UNX) rat model with renal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: During 21,992 person-years of follow-up, 190 patients developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Use of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors and <z:chebi fb="0" ids="35664">statins</z:chebi> in isolation or combination during follow-up was associated with reduced risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> after adjustment for covariates </plain></SENT>
<SENT sid="8" pm="."><plain>The multivariable RERI and AP for the additive interaction between these drug classes for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> were significant (0.53 [95% CI 0.20-0.87] and 2.65 [0.38-4.91], respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>In the UNX rat model, inhibition of the <z:mp ids='MP_0011356'>RAS</z:mp> prevented <z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo> by normalizing hydroxymethylglutaryl-CoA reductase (HMGCR) expression and the insulin-like growth factor-1 (IGF-1) signaling pathway </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Combined use of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors and <z:chebi fb="0" ids="35664">statins</z:chebi> may act synergistically to reduce <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk, possibly via HMGCR and IGF-1 signaling pathways in high-risk conditions such as type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>